Search results for "antibodies" in Articles / App Notes
Article
Process Chromatography: Continuous Optimization
Monoclonal antibodies (mAbs), which today account for approximately 50% of the total revenues of all biopharmaceuticals according to David Westman, global product marketing manager for Cytiva, are typ…
Article
Impact of Manufacturing-Scale Freeze-Thaw Conditions on a mAb Solution
Therapeutic proteins, peptides, and antibodies have emerged as highly effective modern medicines for numerous diseases and disorders (1). Therapeutic monoclonal antibodies (mAbs) represent a rapidly g…
Article
Elucidating Biosimilars Characterization
In addition, some proteins, for example, monoclonal antibodies, have half-lives of weeks. These proteins would, therefore, require sample collection for many weeks to accurately define the pharmacokin…
Article
Best Practices for Selecting a Top-Quality Cell Line
Before scaling up to bioreactors, the productivity level for monoclonal antibodies (mAbs) should be 2–7 g/L (fed-batch culture in shake flask) or greater, observes Selexis CEO Igor Fisch. Once scaled …
Article
Improving Process-Scale Chromatography
More than 40 years of improvement in Protein A chromatography has resulted in well-established, robust purification processes for monoclonal antibodies,” Ljungqvist concludes.
Specifically, multim…
Article
Analysis of Glycosylation in Biosimilars
The structures of protein drugs such as monoclonal antibodies are made more complex by post-translational modifications. The most notable of these is glycosylation, where carbohydrate residues are att…
Article
Implications of Cell Culture Conditions on Protein Glycosylation
Multi-chain proteins, such as IgG antibodies, additionally have a quaternary structure resulting from structural associations between the subunits.
The choice of host-cell line for recombinant pro…
Article
Ligand-Binding Assays and the Determination of Biosimilarity
For monoclonal antibodies (mAbs), which make up a large portion of the biosimilars currently under development, it is important to remember that the different ends of the molecule are involved in bind…
Article
Trends in BioPharma Approvals in 2013
Engineered antibodies
Genentech’s Gazyva represents another milestone in antibody approvals, being the first glycoengineered mAb to come on the market in the US. mAbs are glycoproteins, carrying a…
Article
ADC Development Robust Despite Lackluster Performance
The company has developed a pipeline of ADCs, as well as antibodies and human-derived proteins, that target the tumor-associated stroma. For its ADC development, the company is developing antibodies t…